
Sanofi
SNYNASDAQHealthcareDrug Manufacturers - General
最新数据
US$45.84
+US$0.70 · +1.55%
SNY公司概览
盘中时间采用ET。市场数据可能有所延迟。
GoAI 研究快照
简明呈现最新可用的模型信息。
GoAI评分
Buy
Favorable setup — positive multi-factor alignment
估值
79
Undervalued
动量
38
Weakening
情绪
62
Bullish
风险韧性
74
Moderate Risk
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
人工智能生成的上下文仅供参考,并非投资建议。
公司概况
公司网站Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
- 行业
- Drug Manufacturers - General
- 部门
- Healthcare
- 总部
- FR
- 首席执行官
- Belén Garijo López
- 上市以来
- 2002年7月1日
- 雇员
- 76,493
市场位置
- 成交量
- 186.07万
- 0.58× 平均值
- 平均成交量
- 319.11万
- 日均成交量
- 市值
- 1100.95亿 USD
- 贝塔
- 0.28
- 市场参考 1
财务数据
财务快照
最近十二个月估值与收益率
- 市盈率(TTM)
- 24.14×
- 市净率(TTM)
- 1.36×
- 市销率(TTM)
- 1.94×
- 股息率
- 5.22%
盈利能力和效率
- 毛利率
- 72.77%
- 营业利润率
- 20.58%
- 净利润率
- 8.09%
财务健康
- 负债权益比
- 0.34×
财务报表
利润率趋势
盈利能力占已公布营收的百分比。
损益趋势
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 467.16亿 USD | 442.86亿 USD | 416.18亿 USD | 405.61亿 USD | 391.75亿 USD |
| 销货成本 | 130.49亿 USD | 132.05亿 USD | 126.28亿 USD | 118.82亿 USD | 122.55亿 USD |
| 毛利 | 336.67亿 USD | 310.81亿 USD | 289.9亿 USD | 286.79亿 USD | 269.2亿 USD |
| 研究与开发 | 78.42亿 USD | 73.94亿 USD | 65.07亿 USD | 65.01亿 USD | 56.92亿 USD |
| 销售、一般及管理费用 | 102.42亿 USD | 91.83亿 USD | 89.33亿 USD | 87.39亿 USD | 95.55亿 USD |
| 营业费用 | 240.7亿 USD | 238.29亿 USD | 220.3亿 USD | 185.17亿 USD | 187.94亿 USD |
| 利息收入 | 3.31亿 USD | 4.58亿 USD | 5.31亿 USD | 1.69亿 USD | 312.7万 USD |
| 利息支出 | 6.26亿 USD | 6.23亿 USD | 5.13亿 USD | 3.85亿 USD | 3.77亿 USD |
| 折旧和摊销 | 56.78亿 USD | 35.86亿 USD | 44.29亿 USD | 31.08亿 USD | 33.51亿 USD |
| 营业利润 | 95.97亿 USD | 72.52亿 USD | 69.6亿 USD | 101.62亿 USD | 81.26亿 USD |
| 净利润 | 78.13亿 USD | 55.6亿 USD | 54亿 USD | 83.71亿 USD | 62.23亿 USD |
公司数据更新于 2026年8月24日。
SNY同业公司
持有SNY的ETF
报告持有此股票敞口的交易所交易基金。
VanEck Pharmaceutical ETFPPH4260.84万4.03%10.71亿 USD0.36%US$116.63+1.35%
Fidelity Enhanced International ETFFENI3572.07万0.31%109.6亿 USD0.28%US$41.72+0.77%
First Trust Value Line Dividend Index FundFVD3411万0.41%82.95亿 USD0.62%US$50.70+0.06%
Invesco International Dividend Achievers ETFPID3012.47万3.29%9.23亿 USD0.53%US$23.1266+0.59%
Avantis International Equity ETFAVDE2808.65万0.15%191.01亿 USD0.23%US$94.26+0.87%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH2238.96万2.14%9.33亿 USD0.13%US$29.5672+1.22%
GMO International Value ETFGMOI1847.93万2.90%6.37亿 USD0.60%US$41.625+1.35%
Brown Advisory Sustainable Value ETFBASV806.58万1.91%2.16亿 USD0.71%US$31.9487+0.44%
VanEck Pharmaceutical ETFPPH- 市场价值
- 4260.84万
- 重量
- 4.03%
- AUM
- 10.71亿 USD
- 费用率
- 0.36%
- 价格 / 1日
- US$116.63+1.35%
Fidelity Enhanced International ETFFENI- 市场价值
- 3572.07万
- 重量
- 0.31%
- AUM
- 109.6亿 USD
- 费用率
- 0.28%
- 价格 / 1日
- US$41.72+0.77%
First Trust Value Line Dividend Index FundFVD- 市场价值
- 3411万
- 重量
- 0.41%
- AUM
- 82.95亿 USD
- 费用率
- 0.62%
- 价格 / 1日
- US$50.70+0.06%
Invesco International Dividend Achievers ETFPID- 市场价值
- 3012.47万
- 重量
- 3.29%
- AUM
- 9.23亿 USD
- 费用率
- 0.53%
- 价格 / 1日
- US$23.1266+0.59%
Avantis International Equity ETFAVDE- 市场价值
- 2808.65万
- 重量
- 0.15%
- AUM
- 191.01亿 USD
- 费用率
- 0.23%
- 价格 / 1日
- US$94.26+0.87%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH- 市场价值
- 2238.96万
- 重量
- 2.14%
- AUM
- 9.33亿 USD
- 费用率
- 0.13%
- 价格 / 1日
- US$29.5672+1.22%
GMO International Value ETFGMOI- 市场价值
- 1847.93万
- 重量
- 2.90%
- AUM
- 6.37亿 USD
- 费用率
- 0.60%
- 价格 / 1日
- US$41.625+1.35%
Brown Advisory Sustainable Value ETFBASV- 市场价值
- 806.58万
- 重量
- 1.91%
- AUM
- 2.16亿 USD
- 费用率
- 0.71%
- 价格 / 1日
- US$31.9487+0.44%
继续GoAI的研究
在 GoAI 中研究SNYresearch.disclaimer





